West Affum Holdings v. Vidal: Federal Circuit Appeal Voluntarily Dismissed After 159 Days
West Affum Holdings Dac appealed a patentability determination before the Federal Circuit, asserting rights in US14/485594 — a wearable cardiac defibrillator system that diagnoses arrhythmias differently depending on patient motion. The parties agreed to dismiss under Fed. R. App. P. 42(b) after 159 days, with each side bearing its own costs.
Patentability challenge over motion-aware defibrillator tech ends mid-appeal
Filed on 28 December 2023 at the Court of Appeals for the Federal Circuit, Case No. 24-1297 pitted West Affum Holdings Dac against USPTO Director Katherine K. Vidal in a patentability dispute concerning US Application No. 14/485594. The patent-in-suit describes a wearable cardiac defibrillator system capable of adjusting its arrhythmia diagnostic approach based on detected patient motion — a clinically significant capability designed to reduce false positives and inappropriate shocks in ambulatory patients.
The appeal concluded on 4 June 2024 when the parties jointly agreed to dismiss the proceeding under Federal Rule of Appellate Procedure 42(b), with each side absorbing its own costs. Rule 42(b) governs voluntary dismissal at the appellate level and requires either a stipulation by all parties or a court order. The cost-neutral outcome suggests neither party extracted a financial concession, and no merits ruling was issued — leaving the underlying patentability determination from the USPTO undisturbed by the Federal Circuit.
At 159 days, the case closed well before a typical Federal Circuit appeal would reach oral argument, suggesting the parties reached an accommodation — potentially a licensing arrangement, prosecution concession, or strategic withdrawal — without the need for judicial resolution. The public record does not disclose whether the dismissal was with or without prejudice, which is commercially material: a dismissal without prejudice would preserve West Affum’s ability to renew the challenge, while one with prejudice would foreclose that path entirely.
Filing to Voluntary dismissal in 159 days
159-day Federal Circuit appeal — resolved before full merits briefing cycle typically concludes
Voluntarily dismissed: what the Rule 42(b) exit means for both parties
Rule 42(b) dismissal — appeal ends without merits adjudication
Federal Rule of Appellate Procedure 42(b) allows parties to voluntarily dismiss an appeal by stipulation. The Federal Circuit issued no ruling on patentability — the underlying USPTO determination therefore stands undisturbed. This is a procedural exit, not a substantive win or loss. The absence of a merits ruling means no binding precedent was created and no claim construction was issued.
No merits ruling issuedPublic record is silent on prejudice — a critical open question
A voluntary dismissal ‘with prejudice’ bars the dismissing party from re-filing the same claim; ‘without prejudice’ preserves that right. The court order in this case does not specify which applies. This distinction is commercially significant: if without prejudice, West Affum could potentially pursue further patent prosecution strategies or re-challenge the patentability determination. The public record does not resolve this question.
Prejudice status unconfirmedWest Affum exits without a Federal Circuit ruling in its favour
By agreeing to dismiss, West Affum Holdings forgoes any appellate reversal of the USPTO’s patentability finding. The application US14/485594 remains in whatever state the agency left it. However, voluntary dismissal on agreed terms — with no adverse cost order — suggests the exit was strategic rather than forced, possibly reflecting off-record developments in prosecution or licensing.
Strategic withdrawal likelyMotion-aware defibrillator IP landscape remains unsettled at appellate level
The Federal Circuit’s silence on the merits means competitors and FTO analysts cannot rely on this case as clearing or confirming the patent. Companies developing wearable cardiac monitoring systems with adaptive diagnostic logic should treat US14/485594 as unresolved — the application may still be in prosecution, and West Affum’s IP position in motion-dependent defibrillation technology has not been definitively adjudicated.
FTO position remains unclearFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | West Affum Holdings Dac | Company | Wearable cardiac monitoring IP holding entity — holder of US14/485594Search in Eureka ↗ |
| Defendant | Katherine K. Vidal | Individual | Katherine K. Vidal, Director of the USPTO, defending agency patentability determinationSearch in Eureka ↗ |
| Plaintiff counsel | John Whitaker | Attorney | Counsel for West Affum Holdings DacSearch in Eureka ↗ |
| Plaintiff law firm | Christensen, O’Connor, Johnson, Kindness PLLC | Law Firm | Representing West Affum Holdings DacSearch in Eureka ↗ |
| Defendant counsel | Amy J. Nelson | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Defendant counsel | Farheena Yasmeen Rasheed | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Defendant counsel | Kevin Richards | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Defendant counsel | Michael S. Forman | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The dismissal order under Fed. R. App. P. 42(b) is purely procedural — it confirms the parties agreed to end the appeal and that costs are split, but it adjudicates nothing on the merits of patentability. The Federal Circuit issued no claim construction, no validity ruling, and no guidance on the scope of US14/485594. For practitioners, this means the USPTO’s underlying determination remains the operative authority, and the patent’s enforceability or grantability has not been tested at appellate level.
US14/485594 — Wearable Cardiac Defibrillator with Motion-Dependent Diagnostics
US Application No. 14/485594, published as US20160074667A1, covers a wearable cardiac defibrillator system that modulates its arrhythmia diagnostic algorithms based on detected patient motion. The clinical rationale is significant: traditional wearable defibrillators can misinterpret motion artefacts as life-threatening arrhythmias, leading to inappropriate shocks. By sensing movement and adjusting diagnostic thresholds accordingly, the claimed system aims to improve specificity without sacrificing sensitivity in real-world ambulatory use cases.
From a strategic standpoint, motion-aware diagnostic logic sits at the intersection of wearable medtech, cardiac monitoring, and real-time signal processing — a space attracting significant investment and IP competition from companies including ZOLL Medical, Baxter (via Hillrom/BardyDx), and iRhythm. If US14/485594 ultimately grants in broad form, it could create an assertion position against a wide range of ambulatory cardiac monitoring products that incorporate accelerometer-based noise rejection or motion artefact suppression in their arrhythmia detection pipelines.
Should you run an FTO analysis against US14/485594?
Any R&D team developing wearable cardiac defibrillators, ambulatory ECG monitors, or arrhythmia detection systems that incorporate motion sensing or accelerometer data to adjust diagnostic output should treat this application as a live FTO risk. The application remains unresolved at the Federal Circuit level, meaning its prosecution status and potential grant scope are not yet publicly settled. Companies commercialising motion-compensated cardiac diagnostic wearables in the US market face meaningful uncertainty until the application’s fate is determined.
PatSnap Eureka’s FTO Search Agent enables IP and R&D teams to map the claim scope of US14/485594 against your product’s architecture, identify prior art that may inform invalidity arguments, and monitor prosecution events in real time. Eureka can also surface related continuations or divisional applications that West Affum may have filed — essential intelligence for teams building adaptive cardiac monitoring systems who need to understand the full perimeter of this IP family.
Run a freedom-to-operate analysis on US20160074667A1 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patentability appeals in wearable cardiac device technology
Federal Circuit cases involving USPTO patentability challenges to wearable cardiac monitoring and defibrillator technologies — including motion-sensing and adaptive diagnostic systems.
What this case signals for the wearable cardiac device IP landscape
A voluntary Federal Circuit exit with no cost order suggests off-record resolution — and leaves an important patent application uncharted territory.
No Federal Circuit merits ruling means no precedent — FTO work is still required
Because the case was dismissed under Rule 42(b) before any merits decision, competitors in the wearable cardiac defibrillator space cannot use this outcome to clear freedom-to-operate concerns. US14/485594 remains live from an FTO perspective. Companies building motion-aware diagnostic systems should independently assess the application’s current prosecution status.
Cost-neutral dismissal suggests agreed resolution, not capitulation
When each side bears its own costs in a voluntary Federal Circuit dismissal, it typically signals a negotiated exit — not a party running out of resources or conceding defeat. Monitoring West Affum’s subsequent patent filings, licensing announcements, or continuation applications may reveal what drove the settlement of this appeal.
West v Katherine — key questions answered
The appeal was voluntarily dismissed under Federal Rule of Appellate Procedure 42(b) on 4 June 2024, with each side bearing its own costs. No merits ruling was issued. The Federal Circuit did not adjudicate the patentability of US14/485594, leaving the USPTO’s underlying determination in place.
The patent-in-dispute is US Application No. 14/485594 (published as US20160074667A1), covering a wearable cardiac defibrillator system that adjusts its arrhythmia diagnostic methodology based on detected patient motion. The core innovation is motion-dependent diagnostic logic designed to reduce false positive shock events in ambulatory patients.
No. A voluntary dismissal under Fed. R. App. P. 42(b) is a procedural termination — no merits determination was made. The Federal Circuit did not rule on patentability. The underlying USPTO determination stands, but the appeal’s dismissal does not itself constitute a ruling on the validity or invalidity of US14/485594.
The court order does not specify whether the dismissal was with or without prejudice. This is a material distinction: dismissal with prejudice would bar West Affum from re-challenging the same patentability determination, while dismissal without prejudice would preserve that option. The public record is silent on this point.
In appeals from USPTO patentability determinations — including ex parte appeals and Patent Trial and Appeal Board decisions — the Director of the USPTO is named as the respondent in the Federal Circuit proceeding. Katherine K. Vidal served as USPTO Director at the time this appeal was filed in December 2023, making her the nominal defendant representing the agency’s patentability determination.
PatSnap Eureka searches patents and litigation data to answer instantly.